← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pulmokine, Inc.
Slingerlands, NY
$8,710,559
Total funding
8
Grants
Funding over time
peak $2M · FY2010–17$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,710,559 · 8
By mechanism
R44$5,271,635 · 1
N01$1,553,430 · 1
R43$1,515,534 · 4
N43$224,960 · 1
R03$145,000 · 1
Investigators at Pulmokine, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$1,566,452
R44 · FY2012 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,898
R44 · FY2015 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,751
R44 · FY2017 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,482
R44 · FY2016 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$701,052
R44 · FY2013 · HL
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): IND Enabling Studies for a Novel Inhaled PDGF Receptor Inhibitor to Treat PAH$695,615
N01 · FY2015 · HL
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): IND Enabling Studies for a Novel Inhaled PDGF Receptor Inhibitor to Treat PAH$618,547
N01 · FY2016 · HL
A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH$515,573
R43 · FY2017 · HL
A PDGFR inhibitor for the treatment of pulmonary arterial hypertension$351,008
R43 · FY2010 · HL
A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma$337,324
R43 · FY2016 · HL
A novel JAK inhibitor for the treatment of pulmonary arterial hypertension$311,629
R43 · FY2010 · HL
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): IND Enabling Studies for a Novel Inhaled PDGF Receptor Inhibitor to Treat PAH$239,268
N01 · FY2014 · HL
IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs$224,960
N43 · FY2013 · AI
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension$72,500
R03 · FY2012 · HL
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension$72,500
R03 · FY2011 · HL
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$5,000
R44 · FY2015 · HL